管理所有基因型知识：处理不同耐碳青霉烯类抗生素的定植患者。
Managing All the Genotypic Knowledge: Approach to a Septic Patient Colonized by Different with Unique Carbapenemases.
机构信息
Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA
Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
出版信息
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00029-19. Print 2019 Aug.
Abstract
The recent development of new antimicrobials active against carbapenemase-producing (CPE) has brought new hope for the treatment of infections due to these organisms. However, the evolving epidemiology of bacteria with carbapenemases may complicate management, as providers are faced with treating patients colonized by bacteria producing multiple carbapenemases. Here, we present the clinical course and treatment of bacteremia in a cirrhotic patient known to be colonized with both - and -carrying organisms.
摘要
最近开发出了一些新型针对产碳青霉烯酶（CPE）的抗菌药物，为治疗这些病原体引起的感染带来了新的希望。然而，具有碳青霉烯酶的细菌的流行病学正在不断演变，这可能会使治疗变得复杂，因为临床医生需要治疗那些定植了产多种碳青霉烯酶细菌的患者。在这里，我们介绍了一位已知定植有携带 - 和 - 碳青霉烯酶的生物体的肝硬化患者的菌血症临床病程和治疗情况。
相似文献
1
Managing All the Genotypic Knowledge: Approach to a Septic Patient Colonized by Different with Unique Carbapenemases.管理所有基因型知识：处理不同耐碳青霉烯类抗生素的定植患者。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00029-19. Print 2019 Aug.
2
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.2012 年至 2015 年期间，作为国际最佳耐药监测网络（INFORM）全球监测项目的一部分，分离出携带 OXA-48 酶的肠杆菌科细菌，对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的活性进行评估。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
3
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.比较产碳青霉烯酶与不产碳青霉烯酶的耐碳青霉烯类肠杆菌科细菌血症患者的结局
Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9.
4
Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla and bla .肠杆菌科碳青霉烯类耐药菌在两所伊朗大学医院住院患者中的携带情况的分子特征：同时产生 bla 和 bla 的首次报告
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2127-2135. doi: 10.1007/s10096-017-3035-3. Epub 2017 Jun 21.
5
Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.头孢他啶-阿维巴坦对西班牙感染-碳青霉烯类耐药评估监测试验（iCREST）中尿液标本中产碳青霉烯酶肠杆菌科的活性。
Int J Antimicrob Agents. 2018 Mar;51(3):511-515. doi: 10.1016/j.ijantimicag.2018.01.011. Epub 2018 Jan 31.
6
Colonization of intestinal microbiota with carbapenemase-producing Enterobacteriaceae in paediatric intensive care units in Cairo, Egypt.埃及开罗儿科重症监护病房中产碳青霉烯酶肠杆菌科细菌对肠道微生物群的定植情况。
Arab J Gastroenterol. 2019 Mar;20(1):19-22. doi: 10.1016/j.ajg.2019.01.002. Epub 2019 Feb 4.
7
Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.产 OXA-48 类碳青霉烯酶肠杆菌科导致的血流感染：治疗与生存。
Int J Infect Dis. 2014 Sep;26:51-6. doi: 10.1016/j.ijid.2014.05.012. Epub 2014 Jul 3.
8
A rare cause of infection, Raoultella planticola: emerging threat and new reservoir for carbapenem resistance.一种罕见的感染病原体——植生拉乌尔菌：新出现的威胁及碳青霉烯耐药性的新储存宿主
Infection. 2016 Dec;44(6):713-717. doi: 10.1007/s15010-016-0900-4. Epub 2016 May 4.
9
Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.与碳青霉烯类耐药肠杆菌科感染的流行和治疗相关的因素：在三家三级保健医院进行的一项为期七年的回顾性研究。
Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. doi: 10.1186/s12941-018-0267-8.
10
Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: what should be expected in the future?全球及国家层面产碳青霉烯酶肠杆菌科细菌的演变：未来将会如何？
Enferm Infecc Microbiol Clin. 2014 Dec;32 Suppl 4:17-23. doi: 10.1016/S0213-005X(14)70170-3.
引用本文的文献
1
Microbiological and Clinical Aspects of spp.关于 spp. 的微生物学和临床方面
Front Public Health. 2021 Aug 2;9:686789. doi: 10.3389/fpubh.2021.686789. eCollection 2021.
2
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review.头孢他啶-阿维巴坦用于治疗治疗选择有限的严重革兰氏阴性感染：一项系统文献综述
Infect Dis Ther. 2021 Dec;10(4):1989-2034. doi: 10.1007/s40121-021-00507-6. Epub 2021 Aug 11.
本文引用的文献
1
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.产 OXA-48 碳青霉烯酶肠杆菌科细菌感染患者应用头孢他啶-阿维巴坦治疗的临床特征和预后
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
2
First Report of an OXA-48- and CTX-M-213-Producing Kluyvera Species Clone Recovered from Patients Admitted in a University Hospital in Madrid, Spain.首例产 OXA-48 和 CTX-M-213 型酶的克吕沃尔菌属克隆株的报告，该克隆株从西班牙马德里一家大学附属医院的患者中分离得到。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01238-18. Print 2018 Nov.
3
Treatment of Infections by OXA-48-Producing Enterobacteriaceae.产 OXA-48 肠杆菌科细菌感染的治疗。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01195-18. Print 2018 Nov.
4
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.头孢他啶/阿维巴坦、美罗培南/维巴坦还是两者皆有？临床和处方考虑。
Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576.
5
Emergence and nosocomial spread of ST11 carbapenem-resistant co-producing OXA-48 and KPC-2 in a regional hospital in Taiwan.台湾地区一家医院中产 OXA-48 和 KPC-2 的碳青霉烯类耐药肠杆菌科细菌 ST11 的出现和医院内传播。
J Med Microbiol. 2018 Jul;67(7):957-964. doi: 10.1099/jmm.0.000771.
6
Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections.感染病会诊可降低多重耐药菌感染患者30天和1年的全因死亡率。
Open Forum Infect Dis. 2018 Mar 15;5(3):ofy026. doi: 10.1093/ofid/ofy026. eCollection 2018 Mar.
7
Phenotypic and Genotypic Characterization of Enterobacteriaceae Producing Oxacillinase-48-Like Carbapenemases, United States.产耐酶青霉素酶-48 型碳青霉烯酶肠杆菌科的表型和基因型特征，美国。
Emerg Infect Dis. 2018 Apr;24(4):700-709. doi: 10.3201/eid2404.171377.
8
Intensive Care Unit Wastewater Interventions to Prevent Transmission of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Organisms.重症监护病房废水干预措施以预防多种产碳青霉烯酶肺炎克雷伯菌的传播。
Clin Infect Dis. 2018 Jul 2;67(2):171-178. doi: 10.1093/cid/ciy052.
9
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.沃博巴坦：β-内酰胺酶抑制谱及耐药机制对肠杆菌科活性的影响。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01443-17. Print 2017 Nov.
10
Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae.用于肠杆菌科细菌中碳青霉烯酶产生表型检测的改良碳青霉烯灭活方法
J Clin Microbiol. 2017 Aug;55(8):2321-2333. doi: 10.1128/JCM.00193-17. Epub 2017 Apr 5.
Zotero 插件